Deep Learning Enhanced Detection of Aortic Stenosis - The DETECT-AS-Diagnostic Study
Launched by YALE UNIVERSITY · Dec 19, 2024
Trial Information
Current as of July 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The DETECT-AS Diagnostic Study is a research trial that is looking at how well artificial intelligence (AI) can help detect aortic stenosis, a condition where the heart's aortic valve narrows and makes it harder for the heart to pump blood. The study will use results from simple tests like portable electrocardiograms (ECGs) and cardiac ultrasounds to see if AI can predict the risk of this condition more accurately.
To be eligible for the study, participants need to be at least 70 years old and have a routine visit at one of the clinics involved in the study. However, individuals who have recently had certain heart procedures, have specific heart devices, or have serious health issues like dementia or a life expectancy of less than a year won't be able to participate. If you join the study, you can expect to undergo some easy tests and contribute to important research that might improve how doctors detect aortic stenosis in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 70 years or older
- • Attending a routine outpatient primary care clinic at one of the three enrollment sites
- Exclusion Criteria:
- • Opted out of research studies
- • Non-English speaking
- • Urgent or emergent visits, defined as a visit for an illness or injury that needs attention quickly or is life-threatening
- • Any echocardiogram within 12 months of clinic visit
- • Prior history of moderate or severe AS
- • Prior history of aortic valve replacement or repair, including transcatheter and surgical AVR with either a bioprosthetic or mechanical valve
- • Presence of implantable cardiac devices, including permanent cardiac pacer, implantable cardioverter-defibrillator, or left ventricular assist device
- • Prior heart transplant
- • History of dementia
- • Documented life expectancy of \<1 year or current participation in hospice services.
About Yale University
Yale University, a prestigious Ivy League institution located in New Haven, Connecticut, is renowned for its commitment to advancing medical research and clinical innovation. With a rich history of academic excellence and a robust infrastructure for scientific inquiry, Yale serves as a leading sponsor for clinical trials aimed at improving patient care and developing new therapeutic approaches. The university's multidisciplinary teams of researchers and clinicians collaborate to conduct rigorous and ethical studies, leveraging cutting-edge technologies and methodologies to address critical health challenges. Through its dedication to fostering an environment of inquiry and discovery, Yale University plays a pivotal role in translating research findings into clinical practice, ultimately enhancing health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Houston, Texas, United States
Santa Clara, California, United States
New Haven, Connecticut, United States
Patients applied
Trial Officials
Rohan Khera, MD, MS
Principal Investigator
Yale University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported